The Food and Drug Administration (FDA) has reorganized its Center for Drug Evaluation and Research (CDER), specifically within the Office of Medical Policy (OMP), which was approved by the Secretary of Health and Human Services on November 19, 2024. This reorganization aims to improve the FDA's ability to conduct its public health mission by enhancing its capacity to innovate in clinical trials, using tools such as Artificial Intelligence (AI) and Digital Health Technologies (DHTs). The Division of Clinical Trial Quality has been renamed to the Division of Clinical Innovations to support this focus. This restructuring is intended to foster collaboration, attract a diverse workforce, and modernize policy development to guide innovative drug development practices.
Simple Explanation
The FDA is changing how one of its teams works to be better at helping people get new medicines. They're using new tools like smart computers and digital gadgets to make medicine tests better.